MediciNova News

Express News | MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (Ibudilast) For Chlorine-induced Acute Respiratory Distress Syndrome, Once Issued, This Patent Is Expected To Expire No Earlier Than January 2042

BenzingaMay 14 06:15 ET

Express News | Medicinova - Gets Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for Treating Chlorine-Induced Acute Respiratory Distress Syndrome

ReutersMay 14 06:03 ET

MediciNova: Supplementary explanation of financial results for the 1st quarter of the fiscal year ending 2024/12

Futu NewsMay 9 19:00 ET · Announcements

MediciNova: Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending 2024/12 [US GAAP] (Consolidated)

Futu NewsMay 9 19:00 ET · Announcements

MediciNova | 10-Q: Quarterly report

Futu NewsMay 9 17:03 ET · Announcements

Kasai Kou, etc. [Mysterious brands seen from changes in turnover]

Stock closing price turnover compared to the previous day*＜7256＞Kasai Takumi 263 24 7407700*＜4875＞Medicinova 213 7 717600*＜3645＞Medical N 373 8 219600*＜6062＞Charm Care 1704 199 812500*＜6099＞Elan 1003 84 883800*＜4678＞Hidehide 309 10

Fisco JapanMay 8 18:35 ET

MediciNova Anti-inflammatory Drug Gets Issue Notification for New Patent

Seeking AlphaMay 7 06:46 ET

Express News | MediciNova Inc - New Patent Is Expected to Expire No Earlier Than September 2040

ReutersMay 7 06:00 ET

Express News | Medicinova Receives Issue Notification for New Patent Covering Extended-Release Formulations of Mn-166 (Ibudilast)

ReutersMay 7 06:00 ET

12 Health Care Stocks Moving In Friday's After-Market Session

GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by

BenzingaApr 5 16:31 ET

Express News | Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

Moomoo 24/7Apr 3 02:45 ET

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (Ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).

GlobeNewswireApr 2 19:00 ET

MediciNova Vice President Geoffrey O'Brien Announces Retirement

TipRanksApr 1 16:25 ET

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA

BenzingaMar 27 09:05 ET

Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment

Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sc

BenzingaMar 27 02:40 ET

MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment

By Ben Glickman MediciNova said it had received a Japanese patent allowance for its treatment for macular injury linked to multiple sclerosis. The La Jolla, Calif.-based biopharmaceutical company sa

WSJMar 26 19:21 ET

MediciNova Receives a Notice of Allowance For a New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Japan

MediciNova, Inc (NASDAQ:MNOV) today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.

GlobeNewswireMar 26 19:00 ET

Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstrac

BenzingaMar 21 03:14 ET

MediciNova Announces Two Abstracts Regarding MN-001 (Tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:

GlobeNewswireMar 20 19:00 ET

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Yahoo FinanceMar 20 10:58 ET